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ABSTRACT
Optical diagnostics, though still in the developmental stages, identify and quantitate the spectra of
metabolizes and drugs without puncturing the skin (non-invasive) and without using chemical
reagents. Once they are clinically validated, optical devices will begin to replace many clinical tests
that use chemical reagents for diagnostics, particularly those tests that require regular monitoring and
possess properties that are amenable to spectral analysis. Optical devices have a potentially
important role aboard spacecraft because of the limited space available for maintaining an inventory
of medicines and diagnostic devices. Despite the constraints, the spacecraft must provide the
immediate and constant capabilities for diagnosing and treating a wide range of diseases of the crew.
Maintaining the crews’ health and safety remain the highest priorities.
INTRODUCTION
Although crews are thoroughly examined and treated for illnesses prior to missions, they are
subjected to various stresses during flights that can increase their susceptibilities. They can also be
the unwitting carriers of organisms, many of which are difficult to detect and which might remain
dormant for long periods. Thus, ensuring the health of crews remains a critical element for the
successful completion of the various missions. For extended missions, the spacecraft must stock an
inventory of different diagnostic kits (each containing its own specific reagents) and medications in
order to test for and treat a broad range of diseases accurately and quickly. The diagnostic kits and
devices must conform to the constraints imposed by size, weight, and power consumption. After
their use, the spacecraft must safely store or degrade the chemical reagents, blood and other body
fluids, and the non-reusable devices. In contrast, optical devices perform diagnoses non-invasively,
do not require samples of blood or body fluids, can operate almost continuously without using
reagents or supplies. Thus, optical devices offer potential advantages for diagnostics on extended
missions that are not readily provided by test kits that use chemical reagents.
Tables 1 and 2 show several routine tests now performed exclusively using chemical reagents,
though some of the tests are non-invasive. Once they are clinically validateed optical technologies
will begin to replace many clinical tests that use chemical reagents for diagnostics (Fischbach, 1988),
particularly tests that are amenable to spectral analysis, such as blood chemistry and drug monitoring.
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Source: D.S. Sobel and T. Ferguson. 1985. The People’s Book of Medical Tests. Summit Books, NY. Pgs.
13-14.
STATUS OF NON-INVASIVE DIAGNOSTICS IN DIABETES
The advent of self-monitoring of blood glucose represents the most significant advance in the
treatment of diabetes since the discovery of insulin (ADA 1993). Over the years, self-monitoring
has allowed millions of people with diabetes to manage their disease and improve the quality of their
lives. People with diabetes significantly improve their health when they maintain blood glucose
concentrations within the normal range. Their health improves as a result of reducing the severity of
complications that are associated with diabetes and by delaying the onset of the complications.
Although current invasive devices, when used on a regular schedule, reliably and accurately monitor
blood glucose, they do not meet the special needs of many people. For example, people who are
trying to achieve “tight glycemic control” increase both the frequency of insulin administration and
glucose monitoring. However, they have collectively experienced almost triple the incidence of
hypoglycemia because tight control therapy offers no margin for error. Though highly motivated to
succeed, these people find it difficult to juggle the conflicting demands of strict schedules that
frequent monitoring imposes with hectic and unpredictable activities at home and work. On the
other hand, many people with diabetes are often not sufficiently motivated to adhere to the regular
schedules of self-monitoring and thereby fail to manage the disease properly. They find excuses for
not using current invasive (finger pricking) techniques, such as the cost, pain, inconvenience, social
awkwardness, and burdensome record-keeping. Thus current invasive devices for the selfmonitoring of blood glucose, while undeniably essential, have left many problems unsettled.
In recent years, extensive research efforts have been focused on the development of a noninvasive means of monitoring blood glucose concentrations that people with diabetes can use as
readily at work as at home (Arnold and Small, 1990; Bodenner et al., 1991; Ham et al., 1991, 1994;
Robinson et al., 1992; Small et al., 1993). In order to achieve wide-spread acceptance and improve
motivation, a non-invasive, self-monitoring glucose meter has to be highly reliable, safe, socially
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acceptable, convenient, painless, and affordable. In short the availability of a non-invasive device
that eliminates the shortcomings of the current invasive blood glucose monitoring meters offers a
powerful incentive for improving adherence and attaining tight glycemic control.
Most non-invasive technologies are not new. They developed along with the emergence of
modern medicine and have been thoroughly incorporated into it. Table 3 illustrates a few well
known non-invasive and minimally invasive techniques.

Our research addresses the pressing need of people with diabetes for an improved and simplified
method of monitoring blood glucose. We are developing an optical device that uses near-infrared
spectroscopy for monitoring blood chemistry (glucose) non-invasively (without drawing blood) .
This technology, sometimes called “reagentless chemistry”, involves identification and quantitation
of the spectra of different chemicals in the blood. When fully developed, the patient will use a device
that detects spectral signals that are generated as a result of illuminating a finger (Fig. 1), ear lobe,
lips, underside of the tongue, or other optically translucent area (Ham et al., 1993). Signal
processing techniques are used to remove background noise and quantitate spectral signals (Ham,
1994; Ham et al., 1993, 1994; Ham et al., 1995).
We believe that the non-invasive device for detecting blood glucose must meet at a minimum of
five requirements: (1) identifies and quantitates blood substances by their spectral “fingerprints”
(absorption peaks); (2) measures the substance in the blood directly using a safe, low-intensity, near
infrared source; (3) determines concentrations of blood substances using signal processing
techniques; and (4) measures the substance in the blood independently of both skin pigmentation and
site (finger, web, lips, sublingual, earlobe, etc.) where the light impinges, (5) monitors as frequently
as needed ranging from occasionally to continuously. Table 4 summarizes the blood concentrations
of several substances some of which are readily amenable to spectroscopic analysis.
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Figure 1. Non-invasive glucose monitoring system. This finger represents only one of several
different sites for analyzing concentrations of blood glucose and other constituents.
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Table 4. Blood Concentrations of Representative Substances
Substance
Classification
Normal Concentrations
(mg/dl)
Calcium
9.2-11
essential mineral
Digoxin
.8-2
heart drug increases contractile strength
Gentamicin
4-10
antibiotic
Glucose
70-110
primary energy source
tranquilizer (“sleeping pill”)
Phenobarbital
15-39
Sodium
300-330
essential salt
Urea nitrogen
8-23
end product of protein metabolism
Sources H. Lullmann et al. 1993. Pocket Atlas of Pharmacology. Thieme Medical Publishers, NY.
D.S. Sobel and T. Ferguson. 1985. The People’s Book of Medical Tests. Summit Books, NY.
A robust discrimination strategy which can detect and predict glucose concentrations with an
acceptable level of accuracy using spectrophotometric methods serves as a pivotal element in a
highly reliable non-invasive monitoring system for measuring blood glucose (and other substances).
Oximetry, a non-invasive technique, is widely used for monitoring oxygen levels in blood. Optical
sensors detect the spectral properties of oxygenated and deoxygenated hemoglobin and quantitate
the spectra (Buerk, 1993; pgs. 137-139). The oxygen signal is strong because of the high
concentration of hemoglobin in the blood. By comparison, most other chemicals in the blood are
difficult to monitor because of their extremely low concentrations and overlapping spectra with other
chemicals (Amato, 1992). Thus, the detection and prediction of the spectral signals of most blood
chemicals requires far more elaborate signal processing than for monitoring oxygen levels. We must
overcome six major technical obstacles in developing an optical system, such as: (1) removal of
baseline variations that instrumentation drift and ambient conditions introduce into the spectroscopic
data (Hazen et al., 1994; Small et al., 1993), (2) removal of intrinsic high background absorption due
to water, (3) removal of high frequency noise due to the detector and removing the background
absorption due to water, (4) removal of large numbers of overlapping absorption spectra and
molecular interactions of other blood constituents with glucose, and (5) reduction of degradation of
signal of interest due to interference of other blood substances, i.e., red blood cells (45% of blood
volume), and (6) resolving the major optical properties of skin, which is an anistropic and
inhomogeneous medium (Anderson and Parrish, 1982). During the past two years we have
successfully solved the first three technical obstacles and partially solved the fourth.
To date, we have quantitated levels of blood glucose ranging in concentration from O to 600
mg/dl (100 mg/dl is the normal value) (Ham, 1994; Ham et al., 1994, 1995). The development of the
technique of optical monitoring of blood chemistry represents a high priority for people with diabetes
who presently must prick their fingers several times each day to monitor blood glucose using
chemical reagents (Robinson et al., 1992). Buerk (1993) listed 13 behaviors of an ideal biosensor.
Although these generic behaviors are shared among biosensor types, such as electrochemical,
enzyme-based, and optical, only optical sensors can monitor blood chemistry non-invasively (Tables
2 and 4) and without using chemical reagents. The optical technologies that we and others are
developing for monitoring blood glucose are transferable to many other clinical applications. An
optical device, which can function over wide spectral ranges, can replace a single diagnostic test kit
that is frequently used or replace many different types of test kits. In short, optical sensors offer an
advantage for routine tests that are frequently performed, such as glucose monitoring, and for
extended space missions.
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